FINWIRES · TerminalLIVE
FINWIRES

Jazz Pharmaceuticals Delivered Strong Q1 on Broad-Based Portfolio Growth, RBC Says

By

Jazz Pharmaceuticals (JAZZ) delivered a "strong" Q1 as broad-based growth across its commercial portfolio and pipeline reinforced confidence in the health of the business, RBC Capital Markets said in a report Wednesday.

Q1 revenue of about $1.07 billion topped the consensus estimate of $978 million, driven by strength across nearly "all major assets," the report said, adding that the company maintained its 2026 revenue guidance of $4.25 billion to $4.5 billion, though results could exceed that range.

Concerns remain around future generic competition for the "oxybate franchise" and competitive pressures in oncology, though the firm believes the company's strong execution provides a cushion against potential "erosion." RBC estimates 2026 sales for Xywav at about $1.73 billion with expected "gradual decline" in later years, according to the report.

The report also highlighted the company's "oncology pipeline" as a key focus, citing potential expansion opportunities for Ziihera, strong "initial uptake" for Modeyso, better-than-expected Zepzelca revenue and 15% year-over-year Epidiolex sales growth to $250 million driven by sustained epilepsy-related demand and international expansion.

RBC maintained an outperform rating on Jazz Pharmaceuticals and raised its price target to $258 from $195.

Price: $223.80, Change: $+11.54, Percent Change: +5.44%

Related Articles

Wire

Workiva Q1 Adjusted Earnings, Revenue Rise; Shares Drop After Hours

Workiva (WK) reported Q1 adjusted earnings late Tuesday of $0.77 per diluted share, up from $0.14 a year earlier.Analysts polled by FactSet expected $0.65.Revenue for the three months ended March 31 rose to $247.3 million from $206.3 million a year earlier.Analysts surveyed by FactSet expected $245.2 million.Workiva expects Q2 adjusted EPS of $0.62 to $0.65 on revenue of $250 million to $252 million. Analysts expect EPS of $0.52 on revenue of $252.1 million.The company expects full-year adjusted EPS of $2.85 to $2.95 on revenue of $1.037 billion to $1.041 billion. Analysts expect EPS of $2.71 on revenue of $1.038 billion.Workiva shares fell 4.4% in after-hours trading.

$WK
Wire

SSR Mining Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

SSR Mining (SSRM) reported Q1 adjusted earnings late Tuesday of $1.15 per diluted share, up from $0.41 a year earlier.Analysts polled by FactSet expected $0.84.Revenue in the three months ended March 31 rose to $581.8 million from $316.6 million a year earlier.Four analysts surveyed by FactSet expected $536.4 million.SSR Mining shares rose 8% in after-hours trading.

$SSRM
Wire

Everus Construction Q1 Earnings, Revenue Rise; Shares Gain After Hours

Everus Construction Group (ECG) reported Q1 earnings late Tuesday of $1.14 per diluted share, up from $0.72 a year earlier.Analysts surveyed by FactSet expected $0.81.Revenue for the three months ended March 31 rose to $1.04 billion from $826.6 million a year earlier.Analysts polled by FactSet expected $933.8 million.The company raised full-year revenue guidance to $4.3 billion to $4.4 billion from the prior forecast of $4.1 billion to $4.2 billion.Analysts expect $4.23 billion.Everus shares rose 4.2% in after-hours trading.

$ECG